Medical pioneer Gilead Sciences GILD has seen its stock etch out new 52-week highs as the broader market pulled back sharply ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Gilead Sciences has a better P/E ratio of 305.37 than the aggregate P/E ratio of 65.67 of the Biotechnology industry. Ideally, one might believe that Gilead Sciences Inc. might perform better in the ...

Gilead Sciences, Inc.'s ( NASDAQ:GILD ) recent soft profit numbers didn't appear to worry shareholders, as the ...

The healthcare sector continues to advance with technological breakthroughs and growing demand for medical services, creating ...

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price upped by Wells Fargo & Company from $120.00 to $140.00 ...

The major backer of the lenacapavir roll-out is assuring nervous researchers that they will keep their part of funding ...

The pharmaceutical powerhouse has two drugs that disrupt the transmission of the virus, one of which has been approved for ...

Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), ...

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $140.00.